Warfarin in Preventing Blood Clots in Cancer Patients With Central Venous Catheters

This study has been completed.
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00024297
First received: September 13, 2001
Last updated: August 6, 2013
Last verified: December 2002

September 13, 2001
August 6, 2013
October 1999
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00024297 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Warfarin in Preventing Blood Clots in Cancer Patients With Central Venous Catheters
A Multicenter Prospective Randomized Controlled Trial of Thrombosis Prophylaxis With Warfarin in Cancer Patients With Central Venous Catheters

RATIONALE: Warfarin may be effective in preventing the formation of blood clots in patients with central venous catheters.

PURPOSE: Randomized clinical trial to study the effectiveness of warfarin in preventing blood clots in cancer patients who have central venous catheters.

OBJECTIVES:

  • Determine the utility of warfarin in reducing thrombosis rates in cancer patients with central venous catheters.
  • Compare the thrombosis rates in patients treated with different warfarin dosing schedules.
  • Compare the adverse events and survival of patients receiving or not receiving this drug.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to sclerosant potential of cytotoxic regimen (low vs high), site of placement of catheter (peripheral vs central), and duration of drug administration (brief infusion (under 24 hours) vs prolonged infusion (24 hours and over)). Patients are randomized to 1 of 3 arms.

  • Arm I: Patients receive no warfarin.
  • Arm II: Patients receive oral warfarin daily beginning 3 days before placement of central venous catheter (CVC) and continuing until CVC is removed or thrombosis occurs.
  • Arm III: Patients receive oral warfarin as in arm II, with dose adjustment after CVC placement to achieve and maintain INR level.

Patients are followed at 12 months.

PROJECTED ACCRUAL: A total of 1,400 patients (400 in arm I, 700 in arm II, and 300 in arm III) will be accrued for this study within 2 years.

Interventional
Not Provided
Primary Purpose: Supportive Care
Thromboembolism
Drug: warfarin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
February 2009
Not Provided

DISEASE CHARACTERISTICS:

  • Histologically or cytologically confirmed cancer
  • Planned placement of central venous catheter (CVC) for administration of chemotherapy

    • No use of CVC for additional purposes except for antibiotic therapy or blood products

PATIENT CHARACTERISTICS:

Age:

  • 16 and over

Performance status:

  • Not specified

Life expectancy:

  • Not specified

Hematopoietic:

  • WBC at least 2,000/mm3
  • Platelet count at least 100,000/mm3
  • Hemoglobin at least 10 g/dL
  • No congenital bleeding disorders

Hepatic:

  • Not specified

Renal:

  • Not specified

Other:

  • No contraindication to warfarin
  • No anatomic lesions that bleed (e.g., duodenal ulcers)
  • Not pregnant or nursing
  • Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Not specified

Chemotherapy

  • See Disease Characteristics

Endocrine therapy

  • Not specified

Radiotherapy

  • Not specified

Surgery

  • Not specified

Other

  • No prior enrollment on this study
  • No concurrent therapy that would interfere with study drug
  • No concurrent warfarin
Both
16 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
NCT00024297
CRC-WARP, CDR0000068909, EU-20049, ISRCTN50312145
Not Provided
Not Provided
Cancer Research Campaign Clinical Trials Centre
Not Provided
Study Chair: Annie Young University Hospital Birmingham
National Cancer Institute (NCI)
December 2002

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP